Version history

{
  "session_id": "sess_sda-2026-04-01-gap-v2-68d9c9c1_20260412-080046",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "support",
  "content": "\n\n# Domain Expert Assessment: RBP Dysregulation in ALS-FTD-AD\n\n---\n\n## 1. Translational Potential Ranking\n\n### Tier 1: Highest Potential\n\n**TDP-43-centric LLPS dysregulation as a shared mechanism across ALS-FTD-AD**\n\nThis hypothesis—which the Theorist touched on but underweighted—warrants primary translational focus. TDP-43 pathology is present in approximately 40–55% of clinically diagnosed Alzheimer's cases (LATE-NC: Limbic-predominant Age-related TDP-43 Encephalopathy Neuropathologic Change), providing direct mechanistic overlap. Critically, the AD field already has regulatory-grade biomarkers for neuronal injury (CSF NfL, p-tau/tau ratio) and established trial infrastructure targeting TDP-43 co-pathology. Unlike FUS, which is predominantly an ALS mechanism, TDP-43 connects all three diseases in a clinically meaningful frequency distribution. The current AHEAD 45 trial and similar prevention studies are already collecting CSF and plasma samples that could be retrospectively interrogated for TDP-43 biomarkers.\n\n### Tier 2: Promising but Earlier-Stage\n\n**Stress granule homeostasis as a convergence point for RBP dysfunction**\n\nThis hypothesis has genuine mechanistic appeal because stress granule dynamics integrate upstream proteostatic stress signals that upstream therapies (anti-amyloid antibodies, anti-tau antibodies) do not address. The hypothesis is directly testable in patient-derived iPSC neurons and has a plausible therapeutic entry point. However, the field lacks validated stress granule burden biomarkers for human clinical trials, and pharmacodynamic readouts would require invasive neuronal sampling or speculative CSF assays.\n\n### Tier 3: Mechanistically Interesting but Clinically Premature\n\n**m6A epitranscriptomic rewiring**\n\nThe Theorist's Hypothesis 1 is mechanistically innovative but has the longest developmental arc to clinical relevance. The causal directionality is unresolved, the therapeutic target (METTL3/YTHDF axis) overlaps dangerously with oncogenic pathways, and no AD-specific validation exists for m6A-targeted interventions. This deserves investment as a mechanistic probe in iPSC and animal models, not as a near-term clinical hypothesis.\n\n---\n\n## 2. Clinical Evidence, Safety, and Patient Population Fit\n\n| Hypothesis | Current Clinical Evidence | Safety Considerations | Patient Population Fit |\n|-----------|--------------------------|----------------------|------------------------|\n| **TDP-43 LLPS dysregulation** | Strong indirect evidence: TDP-43 inclusions confirmed in ~50% of AD (LATE); TDP-43 severity correlates with cognitive impairment independent of amyloid/tau burden; FTD-ALS patients with TDP-43 mutations show progressive cognitive decline | Low immediate safety risk for RBP-targeting strategies compared to m6A axis; small molecules modulating TDP-43 LLPS are precedented (e.g., metal chelators in preclinical TDP-43 models) | Excellent fit: patients with TDP",
  "tokens_used": "735"
}